AstraZeneca (Pfizer Bid) Debate

Full Debate: Read Full Debate

Roberta Blackman-Woods

Main Page: Roberta Blackman-Woods (Labour - City of Durham)
Tuesday 6th May 2014

(10 years, 2 months ago)

Commons Chamber
Read Full debate Read Hansard Text

Urgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.

Each Urgent Question requires a Government Minister to give a response on the debate topic.

This information is provided by Parallel Parliament and does not comprise part of the offical record

Vince Cable Portrait Vince Cable
- Hansard - - - Excerpts

That is why I have stressed—it is fair to say that the Opposition spokesman has also stressed it—that we must not approach this matter in a nationalistic way, let alone in an anti-American way. One of the most difficult tasks I have undertaken in this Government was talking to General Motors to try to persuade it to invest heavily in the British car industry. We have no wish whatever to compromise our reputation for being open to good foreign investors.

Roberta Blackman-Woods Portrait Roberta Blackman-Woods (City of Durham) (Lab)
- Hansard - -

The Secretary of State may not have concerns about the impact of the proposed takeover on Britain’s science base, but many others do, including the chancellor of Cambridge university, Lord Sainsbury, and some prominent AstraZeneca investors. Will the Secretary of State say a bit more about why he does not agree with them?

Vince Cable Portrait Vince Cable
- Hansard - - - Excerpts

I do not know the basis on which the hon. Lady invented that question. From the outset of my statement and in all my subsequent comments, I have made it very clear that the interests of British science—R and D and the jobs associated with it—are absolutely at the centre of our concerns. As it happens, I have spoken to Lord Sainsbury, and I am aware of his concerns. I have spoken to other leading members of the scientific community—we are also aware of their concerns—and they acknowledge that we are working as best we can within the constraints we have to secure a good outcome for British science.